Reviewing the Risks of Orthokeratology
-
By
-
Brooke M. Messer, OD, FSLS, FAAO
-
May 1, 2026
-
3 min
By
Brooke M. Messer, OD, FSLS, FAAO
May 1, 2026
Ahead of phase 3 myopia push, late clinical-stage biopharmaceutical company takes on Thomas Ruggia as Chief Executive Officer
May 18, 2026
by Jingjing Wang, Yunsheng Zhang, Hui Wang, Xiaolan Xie, Bidan Zhu
May 11, 2026
Meta-analysis found odds rose most sharply between 1 and 4 hours of daily digital screen exposure before increasing more gradually thereafter
May 21, 2026